Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v14-FR Version v6-FR
Language French French
Date Updated 2023-04-05 2022-09-26
Drug Identification Number 02139561 02139561
Brand name OXYTOCIN INJECTION, USP OXYTOCIN INJECTION, USP
Common or Proper name Oxytocin Injection, USP Synthetic 10 USP units/mL SD Vial 1 mL Oxytocin Injection, USP Synthetic 10 USP units/mL SD Vial 1 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients OXYTOCIN OXYTOCIN
Strength(s) 10UNIT 10UNIT
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging size 1mL 1mL
ATC code H01BB H01BB
ATC description POSTERIOR PITUITARY LOBE HORMONES POSTERIOR PITUITARY LOBE HORMONES
Reason for shortage Other (Please describe in comments) Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-05-01 2022-05-01
Estimated end date 2023-04-30 2022-11-14
Actual end date 2023-04-01
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments On 100% allocation As per our communication dated August 19, 2022 our Oxytocin Injection, USP Synthetic 10 USP units/mL SD Vial 1 mL vial supply interruption was expected to be resolved by January 2, 2023; however, we are pleased to advise that our resolution date has been improved to November 14, 2022. Our allocation plan for our 1mL vial for October remains as previously communicated; contract customers will be allocated 50% of historical monthly demand. Effective November 1, 2022, our 1mL will be on backorder until November 14, 2022. Once available, the product will be placed on 100% allocation. Contract customers will be allocated 100% of historical monthly demand.
Health Canada comments